TD Cowen maintains BridgeBio Pharma at Buy, lowers price target to $100 from $110

TD Cowen kept its Buy rating on BridgeBio Pharma but reduced its price target to $100 from $110, a 9.1% cut. This implies a 41.4% upside from the Oct 29 closing price of $70.73. Recent analyst targets for the stock range from $88 to $156.

Original reporting
Published Oct 30, 2026, 6:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TD Cowen maintains BridgeBio Pharma at Buy, lowers price target to $100 from $110 — source image
Decision brief

The 30-second read

$BBIOBearishMed
01

Why it matters

The target cut may trigger short-term selling pressure but long-term investors may wait for trial outcomes.

02

Market read

Analyst target adjustments are a key driver for biotech stock movements, especially for small-cap companies.

03

What to watch

Upcoming clinical trial data could offset the target reduction if results are positive.

Relevance 6/10Novelty 6/10Timing: immediate

Background

BridgeBio Pharma is a clinical-stage biotech focused on rare diseases; analyst coverage influences its valuation.

Company-level read

Ticker impact

$BBIOBearishHigh confidence
Context

TD Cowen lowered BridgeBio Pharma's price target to $100 from $110.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Target reduction signals weaker outlook, prompting sellers.

Market effects

Potentially drags other biotech stocks as analysts reassess valuations.

U.S. biotech sector may see modest pullback.

Limited to investors tracking BridgeBio and comparable biotech peers.

Counterpoint

Some investors may view the cut as an entry point if they believe the market overreacted.

Key entities

  • TD Cowen

    Equity research firm providing the price target update.

  • BridgeBio Pharma

    Biotech firm whose stock is affected by the target change.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.